Diabetes Mellitus Type 1 — Patent Landscape
2
Approved drugs
150
Active US patents
63/100
Avg vulnerability
$6.3B
Annual revenue covered
Originators in Diabetes Mellitus Type 1
Cliff calendar — next 15 years
4
26
30
27
38
28
15
29
42
30
9
31
2
39
6
40
2
41
Approved drugs ranked by patent estate
| Drug | Originator | Active patents | Avg vuln | Revenue | First cliff |
|---|---|---|---|---|---|
|
Farxiga
DAPAGLIFLOZIN
|
AstraZeneca | 144 | 64 | $6.3B | 2026-08-18 |
|
Inpefa
SOTAGLIFLOZIN
|
Lexicon Pharms Inc | 6 | 61 | — | 2028-05-04 |
Most attackable patents
| Patent | Drug | Type | Vuln | Expiry |
|---|---|---|---|---|
| 7781577 | Inpefa | method of use | 83 | 2028-05-04 |
| 7781577 | Inpefa | method of use | 83 | 2028-05-04 |
| 8476413 | Inpefa | method of use | 83 | 2028-05-29 |
| 8476413 | Inpefa | method of use | 83 | 2028-05-29 |
| 8329648 | Farxiga | method of use | 80 | 2026-08-18 |
| 8906851 | Farxiga | method of use | 80 | 2026-08-18 |
| 8906851 | Farxiga | method of use | 80 | 2026-08-18 |
| 8329648 | Farxiga | method of use | 80 | 2026-08-18 |
| 8906851 | Farxiga | other | 80 | 2027-02-18 |
| 8329648 | Farxiga | other | 80 | 2027-02-18 |
Strongest defences
| Patent | Drug | Type | Vuln | Expiry |
|---|---|---|---|---|
| 7919598 | Farxiga | composition of matter | 10 | 2029-12-16 |
| 7919598 | Farxiga | composition of matter | 10 | 2029-12-16 |
| 7919598 | Farxiga | composition of matter | 10 | 2029-12-16 |
| 7919598 | Farxiga | composition of matter | 10 | 2029-12-16 |
| 7919598 | Farxiga | composition of matter | 10 | 2029-12-16 |
| 7919598 | Farxiga | composition of matter | 10 | 2029-12-16 |
| 7919598 | Farxiga | composition of matter | 10 | 2029-12-16 |
| 7919598 | Farxiga | composition of matter | 15 | 2029-12-16 |
| 7919598 | Farxiga | composition of matter | 15 | 2029-12-16 |
| 7919598 | Farxiga | composition of matter | 15 | 2029-12-16 |
Related
- Diabetes Mellitus Type 1 — full disease profile
- AI Patent Landscape Report — type "diabetes mellitus type 1" for an AI exec memo
- Company Patent Rankings
- Biosimilar Opportunity Scanner